Please Wait
Applying Filters...

Annual Sales of MolPort-002-051-769 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 991Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Ativan

PharmaCompass

01

Brand Name : Ativan

Lorazepam

arrow
AAPS 2024
Not Confirmed

Brand Name : Ativan

arrow
AAPS 2024
Not Confirmed

Lorazepam

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 50

2019 Revenue in Millions : 43

Growth (%) : 16

blank

02

Brand Name : Ativan

Lorazepam

arrow
AAPS 2024
Not Confirmed

03

Brand Name : Ativan

Lorazepam

arrow
AAPS 2024
Not Confirmed

Brand Name : Ativan

arrow
AAPS 2024
Not Confirmed

Lorazepam

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 43

2018 Revenue in Millions : 54

Growth (%) : -20

blank

04

Brand Name : Ativan

Lorazepam

arrow
AAPS 2024
Not Confirmed

Brand Name : Ativan

arrow
AAPS 2024
Not Confirmed

Lorazepam

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 60

2016 Revenue in Millions : 41

Growth (%) : 46

blank

05

Brand Name : Ativan

Lorazepam

arrow
AAPS 2024
Not Confirmed

Brand Name : Ativan

arrow
AAPS 2024
Not Confirmed

Lorazepam

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 54

2017 Revenue in Millions : 60

Growth (%) : -10%

blank